基石药业-B(02616)宣布CS2009(PD-1/VEGF/CTLA-4三特异性抗体)Ⅱ期临床试验联合疗法IND在中国获批，深入探索三抗治疗潜力

Core Insights - Company announced the approval of IND for CS2009, a tri-specific antibody therapy for advanced solid tumors by the NMPA in China [1] Company Developments - CS2009's Phase I study preliminary data has provided confidence to accelerate the Phase II study [1] - The Phase II clinical trial will adopt a multi-cohort parallel expansion design, covering 15 monotherapy/combo therapy cohorts across 9 solid tumor indications, including non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC) [1] - The Phase II clinical trial is currently enrolling patients actively in Australia, and the approval of the IND in China will further expedite the clinical development process [1]